Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy

Area of Science:

• Oncology
• Preclinical Cancer Models
• Drug Discovery

Background:

• Current rodent models (transgenic, subcutaneous xenografts) lack clinical relevance, particularly in metastasis and drug response.
• Existing models fail to accurately mimic human cancer progression and treatment sensitivity.
• There is a critical need for more predictive preclinical cancer models.

Purpose of the Study:

• To develop and validate clinically accurate human cancer models in rodents using surgical orthotopic implantation (SOI).
• To incorporate fluorescent protein technology (GFP, RFP) for in vivo imaging of tumors and metastasis.
• To establish a platform for efficient drug discovery and evaluation, bridging preclinical and clinical development.

Main Methods:

• Surgical orthotopic implantation (SOI) of histologically intact human tumor fragments into corresponding organs of immunodeficient rodents.
• Introduction of green fluorescent protein (GFP) and red fluorescent protein (RFP) genes into cancer cell lines for stable expression in vivo.
• External imaging of tumors and metastasis using fluorescent protein-based systems.

Main Results:

• SOI models accurately reflect human cancer growth and metastatic potential across multiple tumor types.
• Fluorescent protein expression allows for real-time, single-cell level visualization of tumors and metastases.
• SOI models facilitate the discovery and evaluation of novel anti-cancer and anti-metastatic agents, including antiangiogenic drugs.

Conclusions:

• Surgical orthotopic implantation (SOI) provides clinically relevant preclinical models for human cancers.
• Fluorescent protein-tagged SOI models enable advanced in vivo drug screening and mechanistic studies.
• These models serve as a crucial link for translating preclinical findings to clinical cancer therapy.